Question

31-35) Briefly describe how you might design a radio pharmacy in a hospital environment so that it meets or exceeds current regulatory requirements, provides for the ALARA concept as well as minimizes radiation exposure to both patients and clinicians. 36-40) What is the "Blood Brain Barrier" and what does this mean for "diffusible" and "non-diffusible" radiopharmaceuticals for brain imaging? Give at least one example of a diffusible and non-diffusible radiopharmaceutical in your answer. Describe how you might design a new brain tumor imaging radiopharmaceutical. 41-50) A patient arrives at your elinie with a palpable nodule on her thyroid gland. What nuclear medical procedures would you recommend to help diagnose the nature of this nodule and if it were found to be a thyroid tumor what nuclear medical treatment is available? Why or why not might this treatment preferable to other options?

Answer 1

36-40)Blood brain barrier. it isa highly selective semipermeable microvasculature of the central nervous system separates circulating blood from the brain and extracellular fluid in the central nervous system.

Diffusible radio pharmaceutical brain imaging is a process that is used to detect tumors, cerebral stroke, epilepsy. In this process tracers are used which crosses blood brain barrier.

Non diffusible radio pharmaceutical brain imaging is a process that is used to detect metabolic abnormalities of brain where tracers does not cross BBB and localizes to brain.

41-50)​nuclear medical procedures like FDG PET or fluorodeoxyglucose PET, radioactive iodine uptake test can be used.

The available treatment is I-131 radiotherapy which is done by radioactive I-131.Patient is asked to swallow the radio iodine in pill or liquid form thereafter it finishes both cancerous and normal cells of thyroid.

It is preferable as the survival rate of patient is high. but might not preferable as it affects the healthy part of the area.